43rd week of 2017 patent applcation highlights part 26 |
Patent application number | Title | Published |
20170305970 | CONOTOXIN POLYPEPTIDE K-CPTX-BT101, AND METHOD FOR PREPARATION THREOF AND APPLICATION THEREOF - Disclosed are a conotoxin polypeptide κ-CPTx-bt101, a method for preparation thereof, and an application thereof. The conotoxin polypeptide of the present invention consists of 18 amino acids, has a molecular weight of 1872.72 daltons, and has the full sequence KCCTMSVCQPPPVCTCCA (SEQ. ID NO. 1). | 2017-10-26 |
20170305971 | POTENT COMPSTATIN ANALOGS - Compounds comprising peptides and peptidomimetics capable of binding C3 protein and inhibiting complement activation are disclosed. These compounds display greatly improved complement activation-inhibitory activity as compared with currently available compounds. Methods of making and using the compounds are also disclosed. | 2017-10-26 |
20170305972 | Scalable Fermentation Process - This invention provides a robust fermentation process for the expression of a capsid protein of a bacteriophage which is forming a VLP by self-assembly, wherein the process is scalable to a commercial production scale and wherein the expression rate of the capsid protein is controlled to obtain improved yield of soluble capsid protein. This is achieved by combining the advantages of fed-batch culture and of lactose induced expression systems with specific process parameters providing improved repression of the promoter during the growth phase and high plasmid retention throughout the process. | 2017-10-26 |
20170305973 | Rhinovirus C Immunogenic Peptides - A peptide comprising the rhinovirus immunogen peptide of the rhinovirus structural protein 1 (VP1) of rhinovirus C and related vaccines and therapeutic compositions is disclosed. | 2017-10-26 |
20170305974 | AGENT FOR CONTROLLING PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME - An object of the present invention is to optimize, and to increase the accumulation amount of, GP5 antigen, in order to enhance the performance of a PRRS vaccine. The present invention provides a fusion protein comprising an ectodomain (ectGP5) of Glycoprotein 5 (GP5) of porcine reproductive and respiratory syndrome (PRRS) virus, and an adjuvant protein. | 2017-10-26 |
20170305975 | FUSION PROTEINS COMPRISING P3 OF BACTERIOPHAGE - The invention relates to agents and to pharmaceutical compositions for reducing the formation of amyloid and/or for promoting the disaggregation of amyloid proteins. The compositions may also be used to detect amyloid. | 2017-10-26 |
20170305976 | PEPTIDE COMPOSITION AND USES THEREOF - Subject of the invention is a composition comprising at least one fragment of the peptide ESAT-6 and at least one fragment of the peptide CFP-10. Preferably, the fragments comprise at least two sets of peptides, a first set comprising at least one peptide of from about 7 to 14 amino acid residues in length and a second set comprising at least one peptide of from 16 amino acid residues or greater. The invention also relates to diagnostic methods using the composition. | 2017-10-26 |
20170305977 | Polypeptides Having Cellulolytic Enhancing Activity and Polynucleotides Encoding Same - The present invention relates to isolated polypeptides having cellulolytic enhancing activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides. | 2017-10-26 |
20170305978 | BRASSICA NAPUS SEED SPECIFIC PROMOTERS IDENTIFIED BY MICROARRAY ANALYSIS - Provided are constructs and methods for expressing a transgene in plant cells and/or plant tissues using gene regulatory elements obtained from | 2017-10-26 |
20170305979 | CONOTOXIN POLYPEPTIDE K-CPTX-BT102, AND METHOD FOR PREPARATION THREOF AND APPLICATION THEREOF - Disclosed are a conotoxin polypeptide κ-CPTx-bt102, a method for preparation thereof, and an application thereof. The conotoxin polypeptide of the present invention consists of 15 amino acids, has a molecular weight of 1660.61 daltons, and has the full sequence RCRCEQTCGTCVPCC (SEQ. ID NO. 1). | 2017-10-26 |
20170305980 | CA125 GENE AND ITS USE FOR DIAGNOSTIC AND THERAPEUTIC INTERVENTIONS - The CA125 gene has been cloned and multiple repeat sequences as well as the carboxy terminus have been identified. The CA125 molecule comprises three major domains: an extracellular amino terminal domain (Domain 1); a large multiple repeat domain (Domain 2); and a carboxy terminal domain (Domain 3) which includes a transmembrane anchor with a short cytoplasmic domain. The amino terminal domain is dominated by its capacity for O-glycosylation and its resultant richness in serine and threonine residues. An amino terminal extension is presented, which comprises four genomic exons. The molecular structure is dominated by a repeat domain comprising 156 amino acid repeat units, which encompass the epitope binding sites. More than 60 repeat units have been identified, sequenced, and contiguously placed in the CA125 domain structure. More specifically, this invention is directed to a CA125 cDNA sequence which can be introduced into animal or human cells to achieve transcription or expression of the cDNA. | 2017-10-26 |
20170305981 | SYNTHETIC PEPTIDES - Provided herein are compositions comprising synthetic lipase-stimulating peptides, and methods of treating hyper-triglyceridemia and other conditions and diseases therewith. In particular, synthetic peptides (AV-peptides) and peptidomimetics (AV-peptidomimetics) are provided that exhibit the lipase-stimulating activity of apoA-V or an enhancement thereof, as well as methods of use thereof. Provided herein are compositions comprising a peptide or polypeptide having less than 100% sequence identity with full length ApoA-V, encompassing a portion with at least 50% sequence identity with AV199-224. | 2017-10-26 |
20170305982 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PROSTATE CANCER AND OTHER CANCERS - A method of treating a patient who has prostate cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has prostate cancer. A method of treating a patient who has prostate cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the prostate cancer. | 2017-10-26 |
20170305983 | CARDIAC TROPONIN I ULTRA-SENSITIVE DETECTION REAGENT KIT, AND ULTRA-SENSITIVE DETECTION METHOD THEREFOR - A cardiac troponin I ultra-sensitive detection reagent kit, a preparation method, and a detection method. The reagent kit comprises at least one first anti-cardiac troponin I antibody marked with a trace marker and at least one second anti-cardiac troponin I antibody coated on magnetic microspheres, the first anti-cardiac troponin I antibody and cardiac troponin I binding site being different from the second anti-cardiac troponin I antibody and cardiac troponin I binding site. The reagent kit may further comprise a diluent capable of significantly reducing non-specific binding in a detection process, so as to further increase the detection accuracy and sensitivity. The method using the reagent kit to detect cardiac troponin I sensitively and accurately detects the amount of cardiac troponin I in a sample, and provides more timely and reliable information for the early diagnosis and treatment of AMI. | 2017-10-26 |
20170305984 | STATHERIN PEPTIDES - A novel statherin-based fusion peptide is provided. The fusion peptide comprises the statherin peptide, DSSEEKFLR, or a functionally equivalent variant thereof, fused to an acquired enamel pellicle protein or peptide. The statherin-based fusion peptide is useful to treat dental demineralization. Also provided is hydrogel-encapsulated enamel-protective protein or peptides such as statherin, a statherin-based fusion peptide or a histatin. | 2017-10-26 |
20170305985 | Hepatocyte Growth Factor Fragments that Function as Potent Met Receptor Agonists and Antagonists - The NK1 fragment of hepatocyte growth factor (HGF) binds to and activates the Met receptor, a transmembrane receptor tyrosine kinase that plays a critical role in embryonic development and organ formation. The instant application discloses NK1 variant polypeptides which act as agonists or antagonists of HGF. Further disclosed are covalently linked NK1 variant polypeptides. Many of the disclosed variant polypeptides possess improved stability characteristics. | 2017-10-26 |
20170305986 | NOVEL TGF-ALPHA MUTANT PROTEINS - The present invention generally relates to novel TGFα protein mutants having surprisingly superior or beneficial or different characteristics as compared to the native TGFα protein. The invention further relates to the use of the novel TGFα protein mutants in methods and kits for treatment of neurological disorders. | 2017-10-26 |
20170305987 | A tumor necrosis factor-related apoptosis-inducing ligand variant, as well as a preparation method and use thereof - The present invention discloses a tumor necrosis factor-related apoptosis-inducing ligand variant, which is a fusion protein of a tumor necrosis factor-related apoptosis-inducing ligand and an F3 peptide. The F3 peptide is fused to the N-terminus or C-terminus of the tumor necrosis factor-related apoptosis-inducing ligand by a linker. The present invention also discloses a nucleotide sequence, as well as a recombinant vector and a recombinant bacterium comprising same, and also discloses a preparation method and use of the foregoing variant. The tumor necrosis factor-related apoptosis-inducing ligand variant is prepared by means of genetic engineering in the present invention, characterized in that its affinity for tumor cells, ability to induce apoptosis in tumor cells, tumor targeting property and in vivo anti-tumor effect are significantly better than those of the tumor necrosis factor-related apoptosis-inducing ligand. Accordingly, this variant displays good therapeutic effects on tumor treatment and has promising prospects in clinical application. | 2017-10-26 |
20170305988 | METHOD OF USING A PEPTIDE LIBRARY - The present invention provides a peptide selected from the following (i) and (ii): (i) a peptide having the amino acid sequence represented by SEQ ID NO: 1 in the Sequence Listing; and (ii) a peptide having an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO: 1 in the Sequence Listing by the conservative amino acid substitution, deletion, addition, or insertion of 1 to 28 (inclusive) amino acids except at the 1st Xaa to the 11th Xaa counting from the amino terminus. | 2017-10-26 |
20170305989 | IL22 IMMUNOCONJUGATES - The application relates to a conjugate comprising interleukin-22 (IL22) and an antibody molecule. The antibody molecule preferably binds an antigen associated with angiogenesis, such as the ED-A isoform of fibronectin. In particular, the application relates to the therapeutic use of such conjugates in the treatment of a disease/disorder, such as autoimmune diseases, including inflammatory bowel disease (IBD). | 2017-10-26 |
20170305990 | TMEM100 PEPTIDES AND VARIANTS THEREOF AND THEIR USE IN TREATING OR PREVENTING DISEASES OR CONDITIONS - The present invention features compositions of Tmem100 peptides and variants thereof, and their use in treating or preventing diseases or conditions. | 2017-10-26 |
20170305991 | Immunotherapy against melanoma and other cancers - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2017-10-26 |
20170305992 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS - A method of treating a patient who has hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, NSCLC, pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate cancer (PCA), ovarian cancer (OC), melanoma, breast cancer (BRCA), CLL, Merkel cell carcinoma (MCC), SCLC, Non-Hodgkin lymphoma (NHL), AML, gallbladder cancer and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), and uterine cancer (UEC) includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC. A method of treating a patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC. | 2017-10-26 |
20170305993 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS - A method of treating a patient who has hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, NSCLC, pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate cancer (PCA), ovarian cancer (OC), melanoma, breast cancer (BRCA), CLL, Merkel cell carcinoma (MCC), SCLC, Non-Hodgkin lymphoma (NHL), AML, gallbladder cancer and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), and uterine cancer (UEC) includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC. A method of treating a patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC. | 2017-10-26 |
20170305994 | Antagonistic DR3 Ligands - The present invention relates to treatment of inflammatory diseases. In particular, the present invention relates to antagonistic DR3 ligands useful for treating inflammatory diseases. | 2017-10-26 |
20170305995 | CD44V6-Derived Peptides for Treating Metastasizing Cancer - The present invention relates to compounds, pharmaceutical compositions and methods for treating different forms of pancreatic cancer. | 2017-10-26 |
20170305996 | VASCULAR ENDOTHELIAL GROWTH FACTOR FUSION PROTEIN - The present invention relates to a fusion protein binding to a vascular endothelial growth factor (VEGFR) and/or a placental growth factor (PIGF). The fusion protein of the present invention comprises (a) a Fc domain of IgG1, wherein two heavy chains are linked by disulfide bond, and (b) four immunoglobulin domain2s of the VEGFR1, wherein two immunoglobulin domain2s are sequentially fused to each heavy chain of the Fc domain of (a). The present fusion protein has excellent activities of inhibiting cell migration and cell invasion, and has highly enhanced growth inhibition effects to various carcinomas and fibroblasts. Therefore, The fusion protein of the present invention can be used in the preparation of an agent for treating cancers or ocular diseases. | 2017-10-26 |
20170305997 | EGFR and C-Met Fibronectin Type III Domain Binding Molecules - Monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders. | 2017-10-26 |
20170305998 | MODIFIED PIGMENT EPITHELIUM-DERIVED FACTOR (PEDF) PEPTIDES AND USES THEREOF FOR TREATING NEOVASCULAR DISEASES, INFLAMMATORY DISEASES, CANCER, AND FOR CYTOPROTECTION - Disclosed are modified pigment epithelium-derived factor (PEDF) peptides, particulate carrier prodrugs thereof, and pharmaceutical compositions comprising the peptides or particulate carrier prodrugs. The peptides, particulate carrier prodrugs, and pharmaceutical compositions may be used to treat diseases and disorders that are amenable to treatment with anti-angiogenic agents, anti-tumorigenic agents, anti-fibrotic agents, chemotherapy-protecting agents, and immune stimulating agents | 2017-10-26 |
20170305999 | CELL CULTURE MEDIUM - Provided herein, inter alia, are compositions and methods for culturing mammalian cells. In certain aspects, the composition is a medium containing one or more of a lithium ion source, one or more fatty acids, and/or ethanol. Use of any of the cell culture media described herein to culture cells that have been genetically engineered to produce one or more recombinant polypeptides (for example, antibodies) can result in increased titers, a more favorable glycosylation profile, and/or modulated (e.g. decreased) amounts of high and low molecular weight species, and/or modulated (e.g. decreased) amounts of acidic or basic charge variants, compared to cells cultured in a medium that does not contain one or more of a lithium ion source, one or more fatty acids, and/or ethanol. | 2017-10-26 |
20170306000 | METHOD FOR DETERMINING DELETIONS IN HBV PRE-S2 REGION - A method of detecting pre-S | 2017-10-26 |
20170306001 | CHIMERIZATION AND CHARACTERIZATION OF A MONOCLONAL ANTIBODY WITH POTENT NEUTRALIZING ACTIVITY ACROSS MULTIPLE INFLUENZA A H5N1 CLADES - MAb 9F4 provides heterologous protection against multiple influenza A H5N1 clade viruses, including one of the recently designated subclades, namely 2.3.4, through binding to a novel epitope. The present invention relates to isolated mouse-human chimeric (xi) IgG | 2017-10-26 |
20170306002 | A POTENT ANTI-INFLUENZA A NEURAMINIDASE SUBTYPE N1 ANTIBODY - Isolated monoclonal antibodies and antigen binding fragments thereof that specifically bind neuraminidase (NA) of an N1 subtype influenza virus are disclosed herein. These antibodies and antigen binding fragments can be used for the detection of an N1 subtype influenza virus and for determining the immunogenicity of vaccines. The antibodies and antigen binding fragments also can be used for the treatment of a subject to prevent or ameliorate an influenza infection. | 2017-10-26 |
20170306003 | AGENTS FOR INFLUENZA NEUTRALIZATION - The present invention provides antibodies (e.g., monoclonal antibodies, human antibodies, humanized antibodies, etc.), which bind to multiple influenza strains. Such antibodies are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of influenza. | 2017-10-26 |
20170306004 | COMPOSITIONS AND METHODS RELATED TO ANTIBODIES THAT NEUTRALIZE COAGULASE ACTIVITY DURING STAPHYLOCOCCUS AUREUS DISEASE - Embodiments concern methods and compositions for treating or preventing a bacterial infection, particularly infection by a | 2017-10-26 |
20170306005 | ANTI-TENASCIN C ANTIBODIES AND USES THEREOF - There is provided antibodies or antigen-binding fragments, derivatives or variants thereof which are capable of binding to the FBG domain of tenascin-C. There are also provided uses of such antibodies or antigen-binding fragments, derivatives or variants thereof, as well as methods of identifying such antibodies. | 2017-10-26 |
20170306006 | HUMAN NOTCH1 DECOYS - Provided herein are Notch1 fusion proteins. These fusion proteins comprise consecutive amino acids the sequence of which, commencing at the N-terminus of the fusion protein, is identical to the sequence of the amino acids in an extracellular domain of a human Notch1 receptor protein and an Fc portion of an antibody. The amino acid sequence of the extracellular domain (ECD) of the human Notch1 receptor protein commences with the amino acid present at the N-terminus of EGF-like repeat 10 and extends at least through the C-terminal amino acid of EGF-like repeat 23. The N-terminal portion of the ECD of the human Notch1 receptor protein may extend up to the C-terminal amino acid of EGF-like repeat 24 or may extend up to the C-terminal amino acid of EGF-like repeat 36. Compositions of these fusion proteins are also provided. Also provided are methods of treating age-related macular degeneration (AMD), diabetic retinopathy and cancer using the fusion proteins described herein. | 2017-10-26 |
20170306007 | COMPLEMENT COMPONENT C5 ANTIBODIES - The present disclosure relates to antibodies and polynucleotides encoding the same, that may be used to prevent, control, or reduce the activity of the complement pathway. In addition, the disclosure is directed to compositions and methods for diagnosing and treating diseases mediated by or involving complement C5. Specifically, the disclosure is related to C5 antibodies. | 2017-10-26 |
20170306008 | METHODS OF REVERSING CACHEXIA AND PROLONGING SURVIVAL COMPRISING ADMINISTERING A GDF15 MODULATOR AND AN ANTI-CANCER AGENT - Methods are provided for improved treatment of subjects with cancer anorexia-cachexia syndrome, comprising treatment with a combination of at least one anti-cancer agent and at least one GDF 15 modulator. Methods are further provided for improved treatment of subjects with anti-cancer agents which induce cachexia, comprising further treating the subject with at least one GDF 15 modulator. | 2017-10-26 |
20170306009 | METHODS FOR MODULATING THE GLYCOSYLATION PROFILE OF RECOMBINANT PROTEINS USING DISSOLVED OXYGEN - The present invention relates to the field of protein production, and in particular to methods and compositions for modulating glycosylation of recombinant proteins expressed in host cells by supplementing the production media with dissolved oxygen. | 2017-10-26 |
20170306010 | GLYCOENGINEERED BINDING PROTEIN COMPOSITIONS - Provided are glycoengineered populations of Fc domain-containing binding proteins with a reduced anti-drug immune response (ADA). Also provided are methods of treating disease using such compositions, and methods and host for making such compositions. | 2017-10-26 |
20170306011 | MONOCLONAL ANTIBODIES TO PROGASTRIN AND THEIR USES - The present disclosure is directed to progastrin monoclonal antibodies, fragments thereof, compositions comprising progastrin monoclonal antibodies, and methods of making and using progastrin monoclonal antibodies and compositions thereof. The present disclosure is directed to methods of treating colorectal cancer with progastrin monoclonal antibodies and compositions comprising progastrin monoclonal antibodies or fragments thereof. The present disclosure is further directed to methods comprising detection of progastrin, including methods of diagnosing colorectal cancer and methods of monitoring efficacy of anti-cancer therapy in subjects suffering from colorectal cancer. | 2017-10-26 |
20170306012 | MONOCLONAL ANTIBODIES TO PROGASTRIN AND THEIR USES - The present disclosure is directed to progastrin monoclonal antibodies, fragments thereof, compositions comprising progastrin monoclonal antibodies, and methods of making and using progastrin monoclonal antibodies and compositions thereof. The present disclosure is directed to methods of treating colorectal cancer with progastrin monoclonal antibodies and compositions comprising progastrin monoclonal antibodies or fragments thereof. The present disclosure is further directed to methods comprising detection of progastrin, including methods of diagnosing colorectal cancer and methods of monitoring efficacy of anti-cancer therapy in subjects suffering from colorectal cancer. | 2017-10-26 |
20170306013 | SELECTIVE NAV PROTEIN BINDERS - The invention provides antibodies and fragments thereof which bind to human Nav1.7, as well as nucleic acids, vectors, host cells and hybridomas for making the same. Further provided are pharmaceutical compositions for use in treating, preventing and/or reducing the risk of a NAV1.7-mediated conditions or diseases, such as pain, inflammation, and metabolic/chronic diseases. The invention additionally provides methods of generating an antibody against a NAV protein of interest. | 2017-10-26 |
20170306014 | CROSS REACTIVE SIGLEC ANTIBODIES - This invention relates to agents that bind multiple Siglecs, including antibodies that neutralize the inhibitory activity of multiple Siglec-7 and Siglec-9 in lymphocytes. Such agents can be used for the treatment of cancers or infectious disease. | 2017-10-26 |
20170306015 | BINDING MOLECULES, ESPECIALLY ANTIBODIES, BINDING TO L1CAM (CD171) - The present disclosure relates to a binding molecule binding to L1, which is capable of binding to the same L1 epitope recognized by the monoclonal antibody L1-OV52.24, and/or which competes with the monoclonal antibody L1-OV52.24 for binding to L1, wherein the variable part of the light chain of L1-OV52.24 comprises the sequence according to SEQ ID No: 1 or wherein the light chain is encoded by SEQ ID No: 3, and wherein the variable part of the heavy chain of L1-OV52.24 comprises the sequence according to SEQ ID No: 2 or wherein the heavy chain is encoded by SEQ ID No: 4, nucleic acids encoding the binding molecules, uses thereof and pharmaceutical compositions comprising the binding molecules. | 2017-10-26 |
20170306016 | Anti-TIM-3 Antibodies - Anti-TIM-3 antibodies are disclosed, as well as pharmaceutical compositions comprising such antibodies, and uses and methods using the same, such as in the treatment of cancer or infectious disease or T-cell dysfunctional disorders. Bispecific antibodies against TIM-3 and other targets are also disclosed, with a preferred embodiment of a bispecific antibody against TIM-3 and CD3. | 2017-10-26 |
20170306017 | ANTI-CD100 ANTIBODIES AND METHODS FOR USING THE SAME - Compositions and methods are provided for treating diseases associated with CD100, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CD100 monoclonal antibodies have been developed to neutralize CD100. | 2017-10-26 |
20170306018 | BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND ROR1 - The present invention relates to bispecific antibodies against ROR1 and CD3, their manufacture and use. | 2017-10-26 |
20170306019 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF - The invention provides agonistic anti-human VISTA antibodies and antibody fragments. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, GVHD, sepsis and transplant recipients. Screening assays for identifying these agonists are also provided. | 2017-10-26 |
20170306020 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF - The invention provides agonistic anti-human VISTA antibodies and antibody fragments. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, GVHD, sepsis and transplant recipients. Screening assays for identifying these agonists are also provided. | 2017-10-26 |
20170306021 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF - The invention provides agonistic anti-human VISTA antibodies and antibody fragments. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, GVHD, sepsis and transplant recipients. Screening assays for identifying these agonists are also provided. | 2017-10-26 |
20170306022 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF - The invention provides agonistic anti-human VISTA antibodies and antibody fragments. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, GVHD, sepsis and transplant recipients. Screening assays for identifying these agonists are also provided. | 2017-10-26 |
20170306023 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF - The invention provides agonistic anti-human VISTA antibodies and antibody fragments. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, GVHD, sepsis and transplant recipients. Screening assays for identifying these agonists are also provided. | 2017-10-26 |
20170306024 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF - The invention provides agonistic anti-human VISTA antibodies and antibody fragments. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, GVHD, sepsis and transplant recipients. Screening assays for identifying these agonists are also provided. | 2017-10-26 |
20170306025 | COMPOSITIONS COMPRISING COFORMULATION OF ANTI-PD-L1 AND ANTI-CTLA-4 ANTIBODIES - Provided herein are compositions comprising coformulation of anti-PD-L1 and anti-CTLA-4 antibodies, or antigen-binding fragments thereof, and methods of making and using such compositions. In various aspects, stable coformulations of the anti-PD-L1 antibody durvalumab (MEDI4736) and the anti-CTLA-4 antibody tremelimumab are provided. | 2017-10-26 |
20170306026 | ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION - A method of chronically reducing a patient's pathological inflammation via the administration of an agent that specifically binds to an alpha-4 integrin or a dimer comprising an alpha-4 integrin is disclosed. The agent provided must have a binding affinity such that administration is sufficient to suppress pathological inflammation, and the agent is administered chronically to provide long-term suppression of pathological inflammation. | 2017-10-26 |
20170306027 | ALK7 ANTAGONISTS AND USES THEREOF - In certain aspects, the disclosure provides ALK7 antagonists. In certain aspects, these ALK7 antagonists are can be used to improve metabolic parameters in a patient in need thereof. In certain aspects, these ALK7 antagonists can be used to treat or prevent one or more kidney-associated disease or condition in a patient in need thereof. In certain aspects, these ALK7 antagonists can be used to treat or prevent cancer. | 2017-10-26 |
20170306028 | ALK7 Binding Proteins and Uses Thereof - This disclosure provides ALK7-binding proteins such as anti-ALK7 antibodies, and compositions and methods for making the ALK7-binding proteins. In certain embodiments the ALK7-binding proteins inhibit, or antagonize ALK7 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating overweight, obesity, diabetes, overweight, obesity, type 2 diabetes, and their associated conditions; metabolic disorders, and other diseases or conditions that can be treated, prevented or ameliorated by targeting ALK7. | 2017-10-26 |
20170306029 | WNT SIGNALING AGONIST MOLECULES - Wnt signaling agonist compositions and methods for their use are provided. Wnt signaling agonists of the invention comprise a frizzled binding moiety, which is fused or conjugated to an LRP5 or LRP6 binding moiety. | 2017-10-26 |
20170306030 | CHIMERIC ACTIVATORS: QUANTITATIVELY DESIGNED PROTEIN THERAPEUTICS AND USES THEREOF - Aspects of the invention provide methods for harnessing the potential of proteins that occur naturally (e.g., in humans) and that have serious but finite toxicity. Aspects of the invention relate to a quantitative systems-biological and structural approach to design a class of chimeric proteins that avoid the toxicity of protein drugs while retaining their desired activities. In particular, chimeric proteins containing a variant form of a natural protein fused to a targeting moiety may be administered to a subject to target a signal (e.g., induction of apoptosis) to particular cells without having a generalized toxic effect in the subject. | 2017-10-26 |
20170306031 | BINDING PROTEINS AND METHODS OF USE THEREOF - The present disclosure provides binding proteins, such as antibodies, that bind to a GDNF Family Receptor Alpha Like (GFRAL) protein, including human GFRAL protein, and methods of their use. | 2017-10-26 |
20170306032 | SMALL ANTIBODY-LIKE POLYPEPTIDES THAT BIND TO EPHA2 RECEPTOR - The present disclosure is directed to a modified isolated immunoglobulin CH2 domain that specifically binds to an extracellular region of an EphA2 receptor, wherein the amino acid sequence of the modified immunoglobulin CH2 domain includes at least one amino acid substitution, addition or deletion in comparison to a wild type immunoglobulin CH2 domain amino acid sequence, wherein the wild type immunoglobulin CH2 domain amino acid sequence includes SEQ ID NO:1 or SEQ ID NO:2. Heterologous immunoconjugates including fusion proteins and pharmaceutical compositions including the modified isolated immunoglobulin CH2 domain are also disclosed. In addition, methods of treating a disease associated with EphA2 overexpression and methods for killing a target cell expressing EphA2 receptors using the modified isolated immunoglobulin CH2 domain are provided. | 2017-10-26 |
20170306033 | BI-SPECIFIC ANTI-CGRP RECEPTOR/PAC1 RECEPTOR ANTIGEN BINDING PROTEINS AND USES THEREOF - The present invention relates to bispecific antigen binding proteins that are capable of binding to both the human CGRP receptor and the human PAC1 receptor. Pharmaceutical compositions comprising the bispecific antigen binding proteins as well as methods for producing them are also disclosed. Methods of using the bispecific antigen binding proteins to ameliorate or treat conditions associated with the two receptors, such as chronic pain, migraine, and cluster headache, are also described. | 2017-10-26 |
20170306034 | METHODS OF TREATING AUTOIMMUNE DISEASE USING A DOMAIN ANTIBODY DIRECTED AGAINST CD40L - Methods of treating autoimmune diseases, such as primary immune thrombocytopenia (ITP), solid organ transplant rejection, graft-related disease, pemphigus vulgaris, systemic sclerosis, and myasthenia gravis using antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The methods may comprise at least one administration cycle comprising one dose of the antibody polypeptide. The dose may be administered intravenously at a dose from about 75 mg to about 1500 mg. The method normalizes platelet counts in the human patient. | 2017-10-26 |
20170306035 | ANTIBODIES AGAINST OX40 AND USES THEREOF - Provided herein are antibodies, or antigen binding portions thereof, that bind to OX40. Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies. | 2017-10-26 |
20170306036 | BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA - A bispecific bi- or trivalent antibody specifically binding to the two targets which are extracellular domain of human B cell maturation antigen (BCMA) and human CD3epsilon, wherein the variable domains VL and VH in a light chain and the respective heavy chain are replaced by each other, characterized in comprising a constant domain CL wherein the amino acid at position 124 is substituted independently by lysine (K), arginine (R) or histidine (H) (numbering according to Kabat), and in the respective constant domain CH1 the amino acid at position 147 and the amino acid at position 213 is substituted independently by glutamic acid (E), r aspartic acid (D) (numbering according to Kabat). Also the manufacture and use of said antibody. | 2017-10-26 |
20170306037 | COMPOSITIONS AND METHODS OF USE FOR AUGMENTED IMMUNE RESPONSE AND CANCER THERAPY - The present invention provides antibody compositions, including, e.g., antibodies, engineered antibodies and antibody fragments that bind to a tumor necrosis factor receptor superfamily member (i.e., 18). Provided compositions are useful in enhancing CD4+ and CD8+ T cell responses, and in the treatment, amelioration and prevention of diseases that can be counteracted with an augmented immune response, e.g., cancers. Also provided in the invention are polynucleotides and vectors that encode such molecules and host cells that harbor the polynucleotides or vectors; as well as pharmaceutical compositions that comprise such molecules and methods of use thereof. | 2017-10-26 |
20170306038 | COMPOSITIONS AND METHODS OF USE FOR AUGMENTED IMMUNE RESPONSE AND CANCER THERAPY - The present invention provides antibody compositions, including, e.g., antibodies, engineered antibodies and antibody fragments that bind to a tumor necrosis factor receptor superfamily member (i.e., 18), and compositions comprising one or more additional therapeutic agents. Provided compositions are useful in enhancing CD4+ and CD8+ T cell responses, and in the treatment, amelioration and prevention of diseases that can be counteracted with an augmented immune response, e.g., cancers. Also provided are methods of use of combinations that find use in treatment or prevention of cancerous or infectious conditions and disorders. | 2017-10-26 |
20170306039 | HUMAN VH DOMAIN SCAFFOLDS - The invention provides human VH scaffold sequences, libraries derived therefrom and methods of producing. The scaffolds have high expression, solubility and are functional. | 2017-10-26 |
20170306040 | COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH A CD22 ANTIBODY-DRUG CONJUGATE - The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with a CD22 antibody-drug conjugate for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and a CD22 antibody-drug conjugate. | 2017-10-26 |
20170306041 | ANTIBODIES AND ASSAYS FOR DETECTION OF FOLATE RECEPTOR 1 - The invention generally relates to antibodies that bind to human folate receptor and diagnostic assays for folate receptor 1-based therapies. Methods of using the antibodies to monitor therapy are further provided. | 2017-10-26 |
20170306042 | IMMUNOGENIC MODULATION BY ENDOCRINE DEPRIVATION THERAPY IMPROVES SENSITIVITY OF TUMOR CELLS TO IMMUNE MEDIATED LYSIS - The invention is directed to methods of reducing growth of prostate cancer cells and breast cancer cells, which comprises treating such cancer cells with a combination of androgen or endocrine deprivation therapy (e.g., enzalutamide, abiraterone, and tamoxifen) and immunotherapy. | 2017-10-26 |
20170306043 | Monoclonal Antibody Which Specifically Recognizes B Cell Lymphoma and Use Thereof - Provided is a monoclonal antibody which specifically recognizes B cell lymphoma cells and a use thereof. More specifically, provided are the monoclonal antibody; a pharmaceutical composition for preventing or treating B cell lymphoma including the monoclonal antibody; a composition for diagnosing B cell lymphoma including the monoclonal antibody; a method for providing information for diagnosing B cell lymphoma using the monoclonal antibody; a chimeric antigen receptor (CAR) protein including i) the antibody, ii) a transmembrane domain, and iii) an intracellular signaling domain; a recombinant vector which expresses the CAR protein; a CAR-modified T cell transformed with the recombinant vector; a pharmaceutical composition for preventing or treating B cell lymphoma including the CAR-modified T cell; and an antibody-drug conjugate wherein the monoclonal antibody and a drug are conjugated. | 2017-10-26 |
20170306044 | BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND ROR1 FOR USE IN THE TREATMENT OF OVARIAN CANCER - Bispecific antibodies against CD3epsilon and ROR1 are useful for use in the treatmentof ovarian cancer. | 2017-10-26 |
20170306045 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODS - The present invention relates to mono-specific and multi-specific polypeptide therapeutics that specifically target cells expressing prostate-specific membrane antigen (PSMA) and are useful for the treatment of prostate cancer (e.g., castrate-resistant prostate cancer), tumor-related angiogenesis or benign prostatic hyperplasia (BPH). In one embodiment, the multi-specific polypeptide therapeutics bind both PSMA-expressing cells and the T-cell receptor complex on T cells to induce target-dependent T-cell cytotoxicity, activation and proliferation. | 2017-10-26 |
20170306046 | GLYCAN-INTERACTING COMPOUNDS AND METHODS OF USE - The present invention provides glycan-interacting antibodies and methods for producing glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include monoclonal antibodies, derivatives, and fragments thereof as well as compositions and kits comprising them. Further provided are methods of using glycan-interacting antibodies to target cells and treat disease. | 2017-10-26 |
20170306047 | PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION AND TREATMENT, CONTAINING NDRG3 EXPRESSION OR ACTIVITY INHIBITOR AS ACTIVE INGREDIENT, OR NDRG3 PROTEIN-SPECIFIC ANTIBODY AND USE THEREOF - The present invention relates to a pharmaceutical composition for preventing and treating cancer or inflammatory disease, containing an NDRG3 expression or activity inhibitor as an active ingredient. Furthermore, the present invention relates to an NDRG3 protein-specific antibody and a use thereof. Specifically, the antibody to the NDRG3 protein is prepared, and the antibody is used to verify that NDRG3 mediated by lactate generated from a hypoxia reaction promotes cell proliferation, angiogenesis, and cytokine expression through the lactate-NDRG3-c-Raf-ERK signaling pathway, and thus the antibody binding to the epitope of the NDRG3 or a fragment of the antibody can be favorably used in the research of cancer or inflammation occurrence mechanism, the development of novel genes involved in the mechanism, and the development of therapeutic agents and new pharmaceuticals. | 2017-10-26 |
20170306048 | ANTIBODY THERAPEUTICS THAT BIND STAT3 - The present disclosure provides anti-STAT3 antibodies, and antigen-binding portions thereof. In certain embodiments, the antibodies or fragments thereof, are used for the treatment of cancer. | 2017-10-26 |
20170306049 | ANTI-HER3 ANTIBODIES AND USES OF SAME - An isolated polypeptide is provided. The isolated polypeptide comprising an antigen recognition domain specifically binding human HER-3 with a K | 2017-10-26 |
20170306050 | COMPOSITIONS AND METHODS FOR TREATING CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES - The present disclosure provides compositions and methods of use comprising a matrix metalloproteinase-9 (MMP9) binding protein, alone or in combination with one or more additional therapeutic agents for the treatment or prevention of diseases and conditions. | 2017-10-26 |
20170306051 | TREATMENT WITH ANTI-PCSK9 ANTIBODIES - The present invention relates to therapeutic dosing regimens utilizing a dose reduction strategy for treating disorders characterized by marked elevations of low density protein cholesterol (LDL-C) in the plasma of a patient. The subject therapeutic dosing regimens involve delivering as a single administration or plurality of administrations of an anti-proprotein convertase subtilisin kexin type 9 (PCSK9) antagonist antibody as an initial dose of at least about 100 mg, and delivering as a single administration or plurality of administrations at a subsequent dose in an amount that is about the same as the initial dose, or at least half the initial dose after the patient has a LDL-C level at or below about 25, 20, 15 or 10 mg/dL, preferably at or below 10 mg/dL. | 2017-10-26 |
20170306052 | Antibody Molecules Which Bind IL-17A and IL-17F - The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules. | 2017-10-26 |
20170306053 | NOVEL BISPECIFIC ANTIBODY FORMAT - [Problem] Provided is a bispecific antibody with a novel format that retains high binding affinity to both antigens, and can be efficiently produced in a commercial production process. | 2017-10-26 |
20170306054 | REGIOSELECTIVELY SUBSTITUTED CELLULOSE ESTERS AND FILMS MADE THEREFROM - Regioselectively substituted cellulose esters having a plurality of pivaloyl substituents and a plurality of aryl-acyl substituents are disclosed along with methods for making the same. Such cellulose esters may be suitable for use in films, such as +A optical films, and/or +C optical films. Optical films prepared employing such cellulose esters have a variety of commercial applications, such as, for example, as compensation films in liquid crystal displays and/or waveplates in creating circular polarized light used in 3-D technology. | 2017-10-26 |
20170306055 | METHOD OF PRODUCING NANOCELLULOSE - A method of producing nanocellulose includes defibrillating cellulosic raw material by oxidation with an oxidant such as NaClO or H202 and sonication in the presence of a swelling agent. The nanocellusose produced by the method can be used in a method of recycling cellulosic material such as paper, card, cardboard or wood to produce recycled paper. | 2017-10-26 |
20170306056 | NANOCRYSTALLINE CELLULOSE, ITS PREPARATION AND USES OF SUCH NANOCRYSTALLINE CELLULOSE - The present invention relates to nanocrystalline cellulose, an efficient way of its preparation and to uses of such nanocrystalline cellulose. The present invention also relates to porous metal oxides having a chiral nematic structure which are prepared using nanocrystalline cellulose. | 2017-10-26 |
20170306057 | RE-DISPERSED MICROFIBRILLATED CELLULOSE - Methods of improving the re-dispersibility of dried or at least partially dried microfibrillated cellulose, methods of re-dispersing dried or at least partially dried microfibrillated cellulose, compositions comprising re-dispersed microfibrillated cellulose and the use of re-dispersed microfibrillated cellulose in an article, product or composition; and methods of improving the physical and/or mechanical properties of re-dispersed dried or partially dried microfibrillated cellulose. | 2017-10-26 |
20170306058 | METHANOL-TERMINATED POLYMERS CONTAINING ETHER - The present invention relates to polymers functionalized by terminal groups that have, at the chain ends thereof, an ether-containing group of the formula (V) | 2017-10-26 |
20170306059 | UNIFIED COOLING FOR MULTIPLE POLYOLEFIN POLYMERIZATION REACTORS - A system and method for startup of a polyolefin reactor temperature control system having a first reactor temperature control path, a second reactor temperature control path, and a shared temperature control path. In some embodiments, during startup the second reactor temperature control path is configured to allow the temperature of a second reactor to rise due to the heat of the exothermic polymerization reaction occurring within reactor until reaching a predetermined setpoint temperature. In other embodiments, during startup a first reactor temperature control path is configured to include a heat exchanger used as a cooler, and a second reactor temperature control path is configured to include a heat exchanger used as a heater, to raise the temperature of the second reactor until reaching a predetermined setpoint temperature. | 2017-10-26 |
20170306060 | AQUEOUS EMULSION, ADHESIVE COMPOSITION, AND AQUEOUS EMULSION MANUFACTURING METHOD - There is provided an aqueous emulsion derived from a blend comprising an acrylic polymer, wherein the pH of the dispersion medium is less than 7.0, and a water-in-oil emulsion containing a nonionic water-soluble polymer, which aqueous emulsion has viscosity of 1,000 to 15,000 mPa s at 25° C. There are also provided adhesive compositions made using the aqueous emulsion and methods for manufacturing the aqueous emulsion. | 2017-10-26 |
20170306061 | Ziegler-Natta Catalyst Composition for Preparing Polyethylene - The Zigler-Natta catalyst composition of the present disclosure provides uniform polyethylene having a molecular weight in the range from 1 million g/mol to 12 million g/mol. The Zigler-Natta catalyst composition of the present disclosure comprises external electron donor selected from the group consisting of substituted silanediyl diacetate, trialkyl borate and tetraalkoxysilane. | 2017-10-26 |
20170306062 | CURABLE COMPOSITION, RESIST MATERIAL AND RESIST FILM - A problem of The present invention is to provide a curable composition capable of forming a resist which can be easily washed after curing and which has high dry etching resistance and excellent precision of fine pattern transfer, also provide a resist film and a laminate each containing the curable composition, and further provide a pattern forming method using the resist film. The problem of the present invention can be solved by providing a curable composition containing a multifunctional polymerizable monomer (A) which has two or more groups having a polymerizable group and has at least one group Q having a polymerizable group represented by formula (1) below, the amount of silicon atoms in an nonvolatile content being 10 wt % or more. | 2017-10-26 |
20170306063 | PRESSURE-SENSITIVE ADHESIVE SHEET FOR COVERING - A pressure-sensitive adhesive sheet for covering according to an embodiment of the present invention includes a non-crosslinked rubber component having a maximum peak of the molecular weight distribution in the range of 50,000 to 3,000,000, an oil component having a maximum peak of the molecular weight distribution in the range of 1,000 to 20,000, and carbon black. The content of the non-crosslinked rubber component is 25% to 65% by mass, the content of the oil component is 35% to 75% by mass, and the content of the carbon black relative to 100 parts by mass of the total of the non-crosslinked rubber component and the oil component is 1 to 40 parts by mass. | 2017-10-26 |
20170306064 | METALLOCENES AND THEIR USE AS POLYMERIZATION CATALYSTS - Novel unsymmetrical metallocene catalytic compounds of formula (I) are disclosed, as well as catalytic compositions comprising compounds of formula (I). Also disclosed are uses of such catalytic compounds and compositions in olefin polymerisation. | 2017-10-26 |
20170306065 | METHOD FOR PREPARING A DRY-STRENGTH AGENT, IN PARTICULAR GLYOXYLATED POLYACRYLAMIDE - In a method for preparing glyoxylated polyacrylamide, in which an aqueous solution of polyacrylamide is supplemented with ethanediol (glyoxal) under stirring by means of a circulation pump, the reaction is started by the addition of a base, at a basic pH value above 8, and is allowed to react under stirring and/or circulating, whereupon the reaction is stopped by the addition of an acid under stirring and/or circulating after completion of a predetermined reaction time, wherein the method is performed as a discontinuous method in which the quantitative reaction of ethanediol with an excess amount of polyacrylamide in an aqueous basic medium is controlled and/or regulated by at least one, of the following factors: | 2017-10-26 |
20170306066 | SHAPE FORMING PROCESS AND APPLICATION THEREOF FOR CREATING STRUCTURAL ELEMENTS AND DESIGNED OBJECTS - A tool provided that individually creates three-dimensional structural elements which are sequentially positioned into formation of a shaped object. | 2017-10-26 |
20170306067 | IMIDAZOLINE FUNCTIONALIZED OXIDIZED FATTY SUBSTANCE EMULSIFIERS AND METHODS - Imidazoline functionalized oxidized fatty substance emulsifiers are made by obtaining a fatty substance composition; performing an oxidative oligomerization of the fatty substance composition to produce an oxidized fatty substance composition comprising from about 10 to about 75% by weight of oligomeric fatty acid components based on the total weight of fatty acid containing components in the composition; reacting the oxidized fatty substance composition with a polyamine comprising at least one ethylene diamine functional group with at least three hydrogens attached to the two nitrogens to form an aminoethylamido functionalized oxidized fatty substance composition; and forming an imidazoline functionalized oxidized fatty substance emulsifier from the amino-ethylamido functionalized oxidized fatty substance composition. Such compositions are particularly useful in asphalt applications and corrosion inhibition. | 2017-10-26 |
20170306068 | OLEFIN POLYMERIZATION CATALYST SYSTEM COMPRISING MESOPOROUS ORGANOSILICA SUPPORT - A catalyst system comprising a combination of: 1) one or more catalyst compounds comprising at least one oxygen linkage, such as a phenoxide transition metal compound; 2) a support comprising an organosilica material, which may be a mesoporous organosilica material; and 3) an optional activator. Useful catalysts include biphenyl phenol catalysts (BPP). The organosilica material may be a polymer of at least one monomer of Formula [Z | 2017-10-26 |
20170306069 | MULTIMODAL POLYOLEFIN RESIN HAVING HIGH MELT STRENGTH AND MOLDED PRODUCT PREPARED WITH THE SAME - Multimodal polyolefin resin having superior characteristics including moldability, mechanical strength, external appearance, melt strength and a polyolefin resin molded product meeting the requirements: (1) polymerized in the presence of at least two different metallocene compounds as catalysts; (2) matrix index of 2 or less and a melt strength of 4.0 Force (cN) or greater at 190° C.; (3) melt flow index (MIP, 190° C., 5.0 kg load condition) of 0.01 to 5.0 g/10 min; (4) ratio (Mw/Mn, MWD) of weight average molecular weight (Mw) to number average molecular weight (Mn) of 5-35 as measured by gel permeation chromatography; and (5) bimodal or multimodal peaks in a weight average molecular weight distribution measured by gel permeation chromatography, wherein the height ratio of two peaks (the ratio of the height of low molecular weight peak to the height of high molecular weight peak) is 0.7-3. | 2017-10-26 |